NASDAQ:CPHD Cepheid (CPHD) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free CPHD Stock Alerts Notice: Cepheid stock has been delisted and is no longer actively trading. Cepheid is now a division of Danaher Corporation (NYSE:DHR). Add Share Share Today's Range$52.95▼$52.9550-Day Range N/A52-Week Range$25.09▼$53.91VolumeN/AAverage Volume1.25 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Cepheid alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Cepheid Stock (NASDAQ:CPHD)Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to Deoxyribonucleic acid (DNA) amplification and detection. The GeneXpert system is designed for a range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.Read More Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> CPHD Stock News HeadlinesNovember 15, 2023 | forbes.comIn The Fight To End Tuberculosis, This Is The Moment For ProgressJuly 22, 2023 | bbc.comReducing the spread of hepatitis CApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.June 27, 2023 | it.tmcnet.comSpotSee Forms Life Science Advisory Council with Global Industry LeadersMay 14, 2023 | thestreet.comCepheid (CPHD) Showing Signs Of Being Water-Logged And Getting WetterOctober 13, 2022 | businesswire.comGlobal Biochips Market Research Report 2022: Market to Surpass $25+ Billion by 2026 - ResearchAndMarkets.com - Business WireOctober 7, 2022 | businesswire.comThe Worldwide Infectious Disease In Vitro Diagnostics Industry is Expected to Reach $56.6 Billion by 2030 - ResearchAndMarkets.com - Business WireOctober 7, 2022 | benzinga.comGlobal Infectious Disease In Vitro Diagnostics Market Report (2022 to 2030) - High Demand for PoC Facilit - BenzingaApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.October 6, 2022 | globenewswire.comGlobal COVID-19 Testing Industry - GlobeNewswireSeptember 30, 2022 | globenewswire.comLucira Health Reports Pilot Study Interim Results for Chlamydia and Gonorrhea Assays - GlobeNewswireSeptember 30, 2022 | nasdaq.comKey Reasons to Retain Danaher (DHR) Stock in Your Portfolio - NasdaqSeptember 29, 2022 | finance.yahoo.comLucira Health Reports Pilot Study Interim Results for Chlamydia and Gonorrhea Assays - Yahoo FinanceSeptember 29, 2022 | streetinsider.comLucira Health Reports Pilot Study Interim Results for Chlamydia and Gonorrhea Assays - StreetInsider.comSeptember 28, 2022 | streetinsider.comSystemOne Wins Multi-Country, Multi-Device Subcontract through the Infectious Disease Detection and Surveillance Project - StreetInsider.comSeptember 20, 2022 | prnewswire.comGlobal Oncology Molecular Diagnostics Market Report 2022: A $7.28 Billion Market by 2027 - Rise in Demand for Point-of-care Treatment - PR NewswireSeptember 16, 2022 | businesswire.comWorldwide Tuberculosis Diagnosis and Treatment Industry to 2028 - by Diagnosis, Drugs, End-user and Region - ResearchAndMarkets.com - Business WireSeptember 15, 2022 | nasdaq.comDanaher (DHR) to Spin-Off Environmental Unit, Shares Pop - NasdaqSeptember 14, 2022 | businesswire.comGlobal Oncology Molecular Diagnostics Markets, 2022-2027 - Rising Number of R&D Activities & Technological Advancements in Diagnostic Testing - ResearchAndMarkets.com - Business WireSeptember 2, 2022 | bizjournals.comHow monkeypox could help Karius underscore case for its broad pathogen test - San Francisco Business Times - The Business JournalsAugust 29, 2022 | globenewswire.comWith 6.1% CAGR, Global Tuberculosis Diagnostics Market Size Worth USD 3.13 Billion during Forecast [2022-2029] - GlobeNewswireAugust 24, 2022 | globenewswire.comWith 4.1% CAGR, Canada Sexually Transmitted Disease Testing Market Size worth USD 310.5 Million in 2028 - Report by Fortune Business Insights - GlobeNewswireAugust 17, 2022 | gurufocus.comWeitz Analyst Corner: Danaher - GuruFocus.comJuly 28, 2022 | businesswire.comGlobal Covid Diagnostics Market (2022 to 2027) - Launch of Innovative Products Presents Opportunities - ResearchAndMarkets.com - Business WireJuly 23, 2022 | seekingalpha.comDanaher Corporation's (DHR) CEO Rainer Blair on Q2 2022 Results - Earnings Call Transcript - Seeking AlphaJuly 22, 2022 | prnewswire.comGlobal COVID-19 Diagnostics Market Forecasts, 2022-2027: Time to Market and Preparedness Issues - PR NewswireJuly 6, 2022 | globenewswire.comCompanies In The COVID-19 Rapid Test Kits Market Help Ease - GlobeNewswireSee More Headlines Receive CPHD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cepheid and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/28/2016Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryBiotechnology Current SymbolNASDAQ:CPHD CUSIP15670R10 CIK1037760 Webwww.cepheid.com Phone+1-408-5414191FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report CPHD Stock Analysis - Frequently Asked Questions How were Cepheid's earnings last quarter? Cepheid (NASDAQ:CPHD) released its earnings results on Thursday, July, 28th. The scientific and technical instruments company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.14) by $0.19. The scientific and technical instruments company had revenue of $146 million for the quarter, compared to analyst estimates of $145.82 million. The company's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.06) earnings per share. What other stocks do shareholders of Cepheid own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cepheid investors own include Editas Medicine (EDIT), General Electric (GE), Gilead Sciences (GILD), AK Steel (AKS), Danaher (DHR), Intel (INTC), QUALCOMM (QCOM), Alibaba Group (BABA), Ford Motor (F) and FactSet Research Systems (FDS). This page (NASDAQ:CPHD) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cepheid Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
